Welcome to our dedicated page for CS Diagnostics SEC filings (Ticker: CSDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading CS Diagnostics’ (CSDX) regulatory reports can feel like decoding lab protocols. Hundreds of pages describe assay pipelines, FDA submission timelines and automation metrics—information investors need yet struggle to skim. If you have ever typed “CS Diagnostics SEC filings explained simply” or hunted for a “CS Diagnostics quarterly earnings report 10-Q filing,” you know the challenge.
Stock Titan removes that friction. The moment a document posts to EDGAR, our AI extracts the numbers and narratives that matter: “CS Diagnostics 8-K material events explained” when an assay wins clearance, a concise look at a “CS Diagnostics proxy statement executive compensation,” or an alert the instant “CS Diagnostics Form 4 insider transactions real-time” show insider buying. Natural-language summaries, tagged tables and side-by-side comparisons transform dense text into insight, letting you track R&D spend, margins and market expansion without parsing every footnote.
Use the resources below to explore any filing type, then rely on our platform to turn them into decisions:
- “CS Diagnostics annual report 10-K simplified” for full-year performance and pipeline updates
- “CS Diagnostics earnings report filing analysis” to compare assay revenue quarter over quarter
- “CS Diagnostics insider trading Form 4 transactions” and “CS Diagnostics executive stock transactions Form 4” for leadership sentiment
- “understanding CS Diagnostics SEC documents with AI” guides that clarify accounting notes
From granular segment data to real-time “CS Diagnostics Form 4 insider transactions” alerts, Stock Titan’s AI ensures you never miss a disclosure that could move the stock.
CS Diagnostics Corp. (CSDX) reported a quarter marked by a large intangible-asset acquisition funded by equity. The balance sheet shows
Antonio Santoli reports beneficial ownership of 13,596,680 shares of CS Diagnostics Corp. common stock, representing 9.9% of the class. That total includes 3,800,000 shares held directly and 9,796,680 shares issuable on conversion of Series B preferred stock, but conversion is limited by a 9.9% conversion cap in the Series B Certificate of Designation. The filing states the reported ownership excludes any additional Series B shares that cannot be converted due to that cap and excludes securities held in entities where the reporting person lacks voting or dispositive power. The filing also notes the issuer’s Preferred A shares carry supervoting rights representing over 90% of voting power, and the reporting person certifies the position is not held to change or influence control.
Thomas Graus filed a Schedule 13G reporting beneficial ownership of 13,392,434 shares of CS Diagnostics Corp. common stock, equal to
FAQ
What is the current stock price of CS Diagnostics (CSDX)?
What is the market cap of CS Diagnostics (CSDX)?
